コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 plasma or following placement or removal of venous lines.
2 ity in 8 of 27 patients (29.6%) with central venous lines.
3 Twenty-seven patients with permanent central venous lines (13 men and 14 women; mean age +/- SD, 53.8
5 Cardiac pacemakers and reservoirs of central venous lines can induce artifactual (18)F-FDG on CT-corr
7 ed after injection through the right central venous line confirmed the presence of a clot in the supe
8 e field of pediatrics often requires central venous line (CVC - Central Venous Catheter) implantation
9 leukemia (ALL), the optimal time for central venous line (CVL) insertion and the optimal type of CVL
10 ased on number of complications with central venous lines (CVL) and external ventricular drains (EVD)
11 I decreased from 1.8 to 1.1 per 1000 central venous line days/mo, a 36% relative reduction (95% CI, 2
12 e, prolonged immobility, presence of central venous lines, estrogens, and a wide variety of inherited
13 CI: 0.72 to 0.99, p = 0.04), use of central venous lines for >10 days or until hospital discharge (H
14 ell or T cell immunophenotype) and a central venous line in place throughout induction were randomly
15 associated with the use of tunneled central venous lines in immunocompromised children and would sav
16 nsive care unit within 28 days after central venous line insertion) (9.8 +/- 9.9 days vs. 17.9 +/- 5.
17 hing unassisted within 28 days after central venous line insertion) compared with matched control pat
19 strogen state (P = .002), indwelling central venous line (P < .001), and prior PE and/or deep venous